cemiplimab


( Last Updated : October 18, 2021)
Generic Name:
cemiplimab
Project Status:
Received
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Libtayo
Project Line:
Reimbursement Review
Project Number:
PC0262-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (Tumour Proportion Score [TPS] 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or, metastatic NSCLC.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or, metastatic NSCLC.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open09-Sep-21
Call for patient/clinician input closed29-Oct-21
Submission received13-Oct-21
Submission accepted